REDWOOD CITY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and immuno-oncology pathways, will host a conference call and webcast for investors on Tuesday, June 2, 2015 at 7:00 a.m. EDT to discuss data being presented at the 2015 ASCO Annual Meeting, being held May 29-June 2, 2015 in Chicago, IL.
To participate by telephone, please dial 855-420-0692 (Domestic) or 484-756-4194 (International). The conference ID number is 57579568. A live and archived audio webcast can be accessed through the Investors section of the Company's website at http://www.oncomed.com. The web broadcast of the conference call will be available for replay through July 2, 2015.
OncoMed will have a total of three presentations on Monday, June 1, 2015 at the ASCO Annual Meeting covering Phase 1b clinical trial results for tarextumab (anti-Notch2/3, OMP-59R5) in small cell lung cancer (Abstract#7508), demcizumab (anti-DLL4, OMP-18M21) in pancreatic cancer (Abstract #4118) and demcizumab in non-small cell lung cancer (Abstract #8045). Copies of the posters will be available on the OncoMed website following their presentation.
Abstract #7508: Final results of phase 1b of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
Lead author: Dr. M. Catherine Pietanza, MD, of Memorial Sloan-Kettering Cancer Center
Poster Discussion Session 1:15 pm – 2:30 pm CDT: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Abstract #4118: A Phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) & gemcitabine (GEM) +/- paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer.
Lead author: Manuel Hidalgo, MD, PhD, Director of the Centro Integral Oncológico Clara Campal (CIOCC), START Madrid
Poster Session 8:00 am – 11:30am CDT: Gastrointestinal (Noncolorectal) Cancer
Abstract #8045: A Phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) & carboplatin (CARBO) in patients with 1st line non-squamous NSCLC.
Lead author: Dusan Kotasek MBBS, FRACP, Adelaide Cancer Centre
Poster Session 8:00 am – 11:30am CDT: Lung Cancer—Non-Small Cell Metastatic
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cell (CSC) and immuno-oncology pathways. OncoMed has six anti-cancer product candidates in clinical development, the most advanced of which are in randomized Phase 2 clinical trials. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28) each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed recently filed an Investigational New Drug application for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signaling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immuno-oncology product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.
|Media & Investors||Investors|
|OncoMed Pharmaceuticals||Shari Annes|
|Michelle Corral||Annes Associates|
|Senior Director, Investor Relationsfirstname.lastname@example.org|
|and Corporate Communications||(650) 888-0902|
Source:OncoMed Pharmaceuticals, Inc.